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The contraceptive methods most commonly used in the U.S. 
are, in order of popularity, oral contraceptives (OCs), condoms 
and spermicides, withdrawal, diaphragms, rhythm, implants, 
and intrauterine devices (IUDs). Also a 3-month progestin 
injection was recently approved for use in the US. Over a period 
of several years, pregnancy rates were <1% a year for oral 
contraceptives, IUDs, implants, and the progestin injection, and 
about 5% a year for the other methods. 
Oral contraceptives.-Effectiveness does not differ signifi-
cantly among the various combination OCs; if no tablets are 
omitted, the pregnancy rate is <0.2% at the end of 1 year. Low-
dose estrogen pills have fewer side effects than the older high 
dose formulations and should be used by nearly all women. Only 
those who are taking some other medications, particularly drugs 
for epilepsy, should use the higher estrogen dose pills. The 
newer lower dose OCs have very few health risks and many 
health benefits unrelated to contraception. 
Healthy women who do not smoke can take low-dose OCs 
continuously until menopause. However, in women over age 35 
who smoke cigarettes or have other risk factors for heart attack 
( eg, untreated hypertension or vascular disease) and use OCs, 
an increased risk of death has been reported from stroke and 
heart attack. No such risk has been reported with low dose pills, 
but it is still safer for women over 35 not to use them if they 
smoke or have other vascular disease. The risk of stroke was 
previously estimated to be greater in OC users, but recent studies 
in which pills with lower doses of estrogen were used have 
shown the incidence to be no different in healthy OC users than 
in healthy nonusers of similar age. 
The risk of breast cancer is not increased in OC users overall 
or in high risk subgroups such as those with a family history of 
breast cancer or cystic changes in the breast. After 35 years of 
OC use in humans, vast amounts of information have been 
amassed regarding the cancer effects of OCs. Although some 
studies show an increased risk of breast cancer in certain groups 
ofOC users, mainly young women under 35, most studies do not 
confirm such an association and actually show a decreased risk 
of breast cancer association with OC use in women 45 to 55 
when the disease is more common. Several other studies show 
that cervical cancer is increased in OC users, particularly those 
who have used OCs for >5 years. A causal relationship has not 
been established, but such women need to have Pap tests 
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performed at least annually. A number of studies have shown 
that OC use decreases the risk of the lethal uterine and ovarian 
cancers by about 50%, and this reduced risk persists after OC use 
is stopped. Other documented noncontraceptive health benefits 
of OC use include a decreased incidence of abnormal bleeding, 
dysmenorrhea, premenstrual tension, anemia, cystic breast dis-
ease, and functional ovarian cysts. A reduced incidence of tubal 
pregnancy and tubal infection associated with OC use should 
decrease infertility. OC users also have fewer cases of rheuma-
toid arthritis and osteoporosis than nonusers. 
Implants.-Plastic capsules containing levonorgestrol are 
inserted under the skin in the upper arm; when released, the drug 
inhibits ovulation and prevents sperm from penetrating the thick 
cervical mucus. A small incision is made under local anesthesia 
in the office or clinic. Then 6 capsules are inserted through a 
needle in a fanshaped pattern to obtain sufficiently high blood 
levels of the hormone for effective contraception. The incision 
is closed without sutures. The capsules remain in place and are 
effective for 5 years. The major side effects are irregular uterine 
bleeding and no bleeding. Headache and weight gain also could 
prompt premature removal of the capsules. With proper coun-
seling, many women choose to continue using this method of 
contraception after 5 years, but because the capsules are not 
dissolved in the body, they need to be removed and replaced. 
Removal is similar to insertion but more difficult because 
scarring develops around the capsules. Normal ovarian activity 
and return of fertility resume immediately after removal. 
Injections.-Depo-medroxyprogesterone acetate (DMPA), a 
long-acting injectable progestin, is given as a injection once 
every 3 months in the muscle of the buttock or upper arm. The 
major side effect of DMPA is complete disruption of the 
menstrual cycle. As duration of therapy increases, the incidence 
of frequent bleeding steadily declines and the incidence of no 
bleeding steadily increases, so that at the end of 2 years about 
70% of the women treated with DMPA have no menstrual 
bleeding. 
Additional side effects include slight weight gain and, because 
of the long duration of action of the drug, there is a delay in the 
return of fertility for as long as one year, but it does not cause 
sterility. Use ofDMP A does not increase the risk of developing 
any cancer, including breast cancer, and the risk of uterine 
cancer is greatly decreased. DMP A may cause temporary 
osteoporosis which disappears after the injections are stopped. 
Intrauterine device (IUD).-In contrast to other contracep-
tives, only about 1 million women in the U.S. use IUDs for 
contraception, even though they are very effective. IUDs have 
some advantages over OCs: Their effects are limited to the 
female genital tract, and insertion requires only one decision by 
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the patient. Only 2 types of IUDs cur-
rently are marketed in the U.S.; the proges-
terone-releasing IUD needs to be inserted 
annually, the copper-bearing T380A is 
effective for at least 10 years. Pregnancy 
rates at the end of 10 years of use with this 
device are <2%. 
The IUD does not act by causing an 
abortion each month. It acts mainly by 
killing sperm and preventing fertilization 
of the egg. An inflammatory reaction in 
the cavity of the uterus is generally ac-
cepted as the main cause of the contracep-
tive effect. Bacteria are present in the 
uterus for 24 hours after insertion of an 
IUD, and although the cavity rapidly be-
comes sterile, inflammation persists after 
the bacterial infection disappears. The 
inflammatory reaction ceases when the 
IUD is removed and fertility returns 
promptly. Bleeding and pain are the ma-
jor medical reasons for removing an IUD; 
these problems account for >50% of all 
discontinuances and occur in about 15% 
of patients during the first year of use and 
7% during the second year of use. The 
expulsion rate for most devices is greatest 
during the first year (about 10%) and 
occurs most frequently in the first few 
months after insertion. About 20% of ex-
pulsions are unnoticed and can be fol-
lowed by an unintended pregnancy; there-
fore, a plastic string is attached to the IUD 
so the user can check periodically, espe-
cially after menses, to see that the device 
has not been expelled. 
Perforation of the uterus is a potentially 
serious but uncommon problem; for de-
vices in current use it occurs in about 1/ 
1000 insertions. Perforation always oc-
curs during insertion. Perforation should 
always be suspected if the patient cannot 
feel the string but did not notice that the 
device was expelled. All IUDs in the 
abdominal cavity should be removed, as 
they can cause bowel scarring. 
Infection of the endometrial cavity oc-
curs at the time of IUD insertion and 
clears after 24 hours. IUD tail strings do 
not provide continuous access for bacte-
ria to enter the uterus. Pelvic infections 
occurring after an IUD has been in place 
for ~30 days are sexually transmitted and 
are not caused by the IUD; they can be 
treated without removing it, unless the 
infection is severe or the patient is preg-
nant. Routine antibiotic use during inser-
tion is not cost-effective. An IUD should 
not be inserted if there is clinical evidence 
of cervical infection. Individuals at high 
risk for developing PID including those 
with a prior history of PID, and women 
with multiple sexual partners should use 
condoms or a diaphragm together with an 
IUD. 
Pregnancies overall are effectively pre-
vented with IUDs; however, a woman 
who becomes pregnant with an IUD in 
place has about a ten-fold greater than 
normal (or 3% to 9%) chance of having a 
tubal pregnancy. If a woman who be-
comes pregnant with an IUD in place 
wishes to continue the pregnancy and the 
tail string is visible, the IUD should be 
removed, since the spontaneous abortion 
rate is lower after removal of the device. 
Several long-term studies have shown no 
evidence that IUDs increase the risk of 
cervical or uterine cancer. 
CHART comes 
to Kaimuki! 
Now 3 convenient 
locations to serve you 
CHART Rehab has recently opened its East Oahu 
Satellite Clinic, CHART's third location in Hawaii. 
Located right in the Kaimuki Municipal Parking Lot at 
3566 Harding Ave. Suite 101, this new location has 
plenty of parking and easy access to and exit from H-1. 
JACl-1\RT 
Comprehensive Health and 
.Active Rehabilitation Training 
-
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East Oahu: 735-1595 
Honolulu: 841-6006 
Waipahu: 671-1711 
